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Anti‑integrin αv therapy improves 
cardiac fibrosis after myocardial 
infarction by blunting cardiac  PW1+ 
stromal cells
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Nathalie Mougenot4, Sophie Nadaud2, Catherine Blanc5, Clément Delacroix1, 
Solenne Chardonnet5, Cédric Pionneau5, Claire Perret2, Elisa Yaniz‑Galende2, 
Nadia Rosenthal3, David‑Alexandre Trégouët2,6, Giovanna Marazzi1, 
Jean‑Sébastien Silvestre1, David Sassoon1 & Jean‑Sébastien Hulot1*
There is currently no therapy to limit the development of cardiac fibrosis and consequent heart failure. 
We have recently shown that cardiac fibrosis post‑myocardial infarction (MI) can be regulated by 
resident cardiac cells with a fibrogenic signature and identified by the expression of PW1 (Peg3). Here 
we identify αV‑integrin (CD51) as an essential regulator of cardiac  PW1+ cells fibrogenic behavior. 
We used transcriptomic and proteomic approaches to identify specific cell‑surface markers for 
cardiac  PW1+ cells and found that αV‑integrin (CD51) was expressed in almost all cardiac  PW1+ cells 
(93% ± 1%), predominantly as the αVβ1 complex. αV‑integrin is a subunit member of the integrin 
family of cell adhesion receptors and was found to activate complex of latent transforming growth 
factor beta (TGFβ at the surface of cardiac  PW1+ cells. Pharmacological inhibition of αV‑integrin 
reduced the profibrotic action of cardiac  PW1+CD51+ cells and was associated with improved cardiac 
function and animal survival following MI coupled with a reduced infarct size and fibrotic lesion. These 
data identify a targetable pathway that regulates cardiac fibrosis in response to an ischemic injury 
and demonstrate that pharmacological inhibition of αV‑integrin could reduce pathological outcomes 
following cardiac ischemia.
Heart failure (HF) remains a leading cause of mortality and hospitalization worldwide and represents a heavy 
financial burden on health care  systems1–6. Current pharmacological treatments limit the peripheral conse-
quences of cardiac dysfunction, but therapeutic approaches that impact primary adverse cardiac remodeling 
at the myocardial level are limited. While the etiology of HF is diverse, HF is typically associated with a range 
of physiological and morphological changes including fibrosis within the  myocardium7–9. Cardiac fibrosis is 
characterized with the excessive production and deposition of extracellular matrix (ECM) proteins within the 
myocardium that results in normal tissue architecture disruption, reduced tissue compliance, and mechanical 
and electrical dysfunction, consequently leading to  HF10,11. The mechanisms underlying cardiac fibrosis are 
incompletely understood, thereby impeding the development of effective anti-fibrotic therapeutics to comple-
ment the current therapies for  HF9,11,12.
Activated cardiac fibroblasts are essential for the production of ECM proteins that accumulate during 
cardiac fibrosis; however, recent studies have established that cardiac fibroblasts represent a heterogeneous 
cell  population10–14. The exact nature of activated fibroblasts and consequently the sources of cardiac fibrosis 
remain  unclear9,12. Different mechanisms underlying fibrosis have been reported including the activation and 
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1Université de Paris, PARCC, INSERM, 56 Rue Leblanc, 75015 Paris, France. 2Sorbonne Université, UPMC Univ 
Paris 06, INSERM, Institute of Cardio Metabolism and Nutrition (ICAN), Paris, France. 3The Jackson Laboratory, Bar 
Harbor, ME, USA. 4Sorbonne Université, UPMC Univ Paris 06, PECMV, UMS28, Paris, France. 5Sorbonne Université, 
Inserm, UMS Omique, Plateforme Post-génomique de la Pitié-Salpêtrière, P3S, 75013 Paris, France. 6INSERM 
UMR_S 1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France. 7These 
authors contributed equally: Marion Bouvet and Olivier Claude. *email: jean-sebastien.hulot@aphp.fr
2Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11404  | https://doi.org/10.1038/s41598-020-68223-8
www.nature.com/scientificreports/
proliferation of resident  fibroblasts15, transformation of endothelial and/or epicardial cells after injury through 
endothelial-mesenchymal transition and epithelial–mesenchymal transition  respectively16,17, and migration of 
hematopoietic bone marrow-derived cells and perivascular  cells18. Another model proposes the activation of 
tissue-resident progenitor populations in response to stress that serves as a major cellular source of organ fibro-
sis, including the heart. In a recent study, we described a novel population of cardiac stromal cells that resides 
in the myocardium and exhibits a fibrogenic fate in response to cardiac ischemic  injury19. This population was 
identified based on the expression of the pan-stem cell marker, Pw1/Peg3 (referred hereafter as PW1)20,21, using 
a transgenic Pw1-beta galactosidase (β-gal) reporter mouse model  (Pw1nLacZ). We found that at least ~ 22% of 
fibroblasts in the fibrotic region of ischemic hearts were derived from PW1-expressing cells, demonstrating that 
cardiac  PW1+ cells directly contribute to cardiac fibrosis. However, the exact pathways mediating the fibrogenic 
activity of cardiac  PW1+ cells remain to be elucidated.
PW1 is a zinc finger transcription factor and cell stress mediator, expressed in the nucleus and cytosol of 
cells. Therefore, we set out to identify specific cell surface markers for cardiac  PW1+ cells under physiological 
and pathological situations using a combination of transcriptomics and proteomics approaches. This combined 
approach led to the identification of αV-integrin (CD51, encoded by Itgav) which is detectable in > 90% of cardiac 
 PW1+ cells. αV-integrin is a subunit member of the integrin family of cell adhesion receptors and previous studies 
show that these molecules are central mediators of organ fibrosis through the TGF-beta signaling  pathway22,23. 
We found that αV-integrin is directly involved in directing the fibrogenic cell fate of cardiac  PW1+ cells and 
specifically the blockade of αV-integrin results in a marked reduction in cardiac  PW1+ fibrotic activation as well 
as in cardiac fibrosis post-myocardial infarction (MI) in vivo.
Results
Characterization of the cardiac  PW1+ cell membranome. We first characterized the transcriptome 
profile of cardiac  PW1+ cells by RNA-seq. We used  PW1nLacZ reporter mice to fluorescence-activated cell sort-
ing (FACS)-isolate cardiac  PW1+ cells from sham-operated hearts and post-MI hearts obtained 7  days after 
left anterior descending artery (LAD) ligation, as previously  described19,20. We then filtered, aligned, quality-
controlled RNA-seq output files to predict amino acid sequences of the corresponding genes, and applied a series 
of bioinformatic algorithms to identify putative membrane proteins (Fig. 1A). We considered proteins with a 
predicted N-terminal endoplasmic reticulum targeting signal peptide and predicted transmembrane domains 
but without intracellular localization signals (i.e., no endoplasmic reticulum retention signal motif and no mito-
chondrial targeting peptide or nuclear export signal). By progressive filtering, we generated a list of 2,040 can-
didates expressed in cardiac  PW1+ cell membranes under both normal and ischemic conditions (Fig. 1B). The 
characteristics of these 2,040 candidates were subsequently screened using available databases to identify 913 
candidates expressed in the plasma membrane of cardiac  PW1+ cells (Fig. 1C). In parallel, we used the same 
strategy to define the surface membranome of other cell types, including cardiomyocytes (CMs), non-myocytes 
heart fractions, and mouse embryonic stem cells, and performed a final screen to limit our list to 378 candi-
dates, which were present in the datasets obtained from cardiac  PW1+ cells (Fig. 1C). Functional enrichment 
analyses of these cardiac  PW1+-specific and condition-insensitive cell surface markers allowed us to identify an 
important number of transmembrane receptors and transporters, and a smaller proportion of ion channels and 
enzymes (Fig. 1D), although the molecular function for the majority of the identified candidates was undefined.
In parallel to the transcriptomic approach, we performed a proteomic analysis of FACS-isolated cardiac  PW1+ 
cells using mass spectrometry (MS) (Fig. 2A). The expression of 1,885 membrane proteins was found and their 
characteristics were subsequently screened using available databases to identify 230 proteins with confirmed 
plasma membrane location. We then made a direct comparison between the transcriptomic and proteomic data-
sets and cross-identified nine candidates obtained with both approaches (Fig. 2B). These nine cell surface proteins 
comprised three transporters, four receptors, and two enzymes and were primarily involved in cell motility, 
adhesion to the matrix, inflammatory response and response to wounding (Fig. 2C,D). Five of these candidates 
have been previously described in non-cardiac cells as plasma membrane clusters of differentiation (i.e., CD51-
Itgav, CD140a-Pdgfra, CD172a-Sirpa, CD39-Entpd1, and CD163) and were thus chosen for further analysis.
αV‑integrin (CD51) is highly expressed on cardiac  PW1+ cells. The expression of these five cell 
surface markers was analyzed by cytometry in 5-dodecanoylaminofluorescein di-β-d-galactopyranoside posi-
tive  (C12FDG+) cells isolated from  PW1nLacZ reporter mouse hearts. We observed that 92.98% ± 1.01% of car-
diac  PW1+ cells express αV-integrin (CD51) (Fig. 3A); the remaining four markers, as well as the typical adult 
stem cell markers (i.e., CD44, CD34, and CD166), were expressed in a lower proportion of cardiac  PW1+ cells 
(i.e., around 50%; Fig. 3B). In order to eliminate hematopoietic circulating cells from the resident stromal cells, 
further analyses of sorted  CD45−Ter119- cardiac cells revealed the strong co-expression of the PW1 reporter 
and αV-integrin (CD51) expression, confirming that the resident cardiac  PW1+ cells exhibit high level expres-
sion of αV-integrin (Fig. 3C,D). The  FDG+CD45−Ter119− cardiac cells were also characterized with high level 
expression of CD140a (i.e., platelet-derived growth factor receptor alpha [PDGFRα]), another candidate from 
our membranome study (Fig.  2D; SI Fig.  S1A). Reciprocally, αV-integrin (CD51) expression was observed 
in the majority of  FDG+CD45+Ter119− cardiac cells (Fig.  3E), which were negative for PDGFRα expression 
(SI Fig. S1B). We then analyzed αV-integrin (CD51) protein expression in CMs and non-myocytes fractions 
freshly isolated from normal mouse hearts. HUVEC cells were used as positive  controls24. As a result, CD51 
expression was exclusively detected in the non-CM fraction (Fig. 3F; SI Fig. S2A). We FACS-sorted  PW1+ and 
 PW1− cell fractions from normal and ischemic mouse hearts and detected CD51 expression mainly in the car-
diac  PW1+ cells (Fig. 3G; SI Fig. S2B), consistent with the results of transcriptomic, proteomic, and cytometry 
analyses. Western blot analysis further confirmed the significant increase in αV-integrin (CD51) expression in 
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Figure 1.  Bioinformatic membranome analysis. (A) Experimental strategy and bioinformatic algorithm to 
identify putative membrane proteins in FACS-purified  PW1+ cardiac cells. (B)  PW1+ cell putative membranome: 
2,113 and 2,284 sequences were identified in cells from sham and ischemic hearts, respectively. A total of 2,040 
sequences were identified under both conditions. (C) Experimental strategy to validate the newly identified 
candidates specifically expressed in the plasma membrane of  PW1+ cardiac cells. (D) Molecular function of 
the 378  PW1+ cell-specific membrane proteins. ER, endoplasmic reticulum, FACS, fluorescence-activated cell 
sorting.
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Figure 2.  Proteomic cross-validation of cardiac  PW1+ new cell surface markers. (A) Experimental strategy 
to identify the membrane proteins observed in the full proteome of FACS-purified  PW1+ cardiac cells. (B) 
Comparison between the two strategies cross-validates the expression of nine candidates. (C) Overlap between 
gene ontology categories of the newly identified cell surface markers for cardiac  PW1+ cells obtained with 
ConsensusDB. (D) List of genes, IDs, aliases, categories and molecular functions of the nine candidates.
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Figure 3.  Itgav (CD51) is identified as a sensitive cell surface marker of cardiac  PW1+ cells. (A,B) Analysis of the 
expression of the newly identified cell surface markers (A) or typical cell surface markers (B) in  PW1+ cardiac cells 
by flow cytometry. N > 10. Graphs show mean ± SD. (C) Analysis strategy to isolate  Ter119− cells. (D,E) CD51 and 
FDG expression in  CD45−Ter119− cells (D) and  CD45+Ter119− cells (E). (F) Cardiomyocytes (CM) and non-CM 
cells were isolated from wild-type adult mouse hearts and analyzed by western blotting for the expression of CD51. 
Proteins from HUVEC were used as positive controls. Ponceau red staining showed equal protein loading. (G) 
 PW1+ and  PW1− fractions were FACS-isolated from sham (left panel) and ischemic (7 days post-MI, right panel) 
hearts of adult  PW1nLacZ mice and pooled to analyze the expression of CD51 by western blotting. Proteins from 
HUVEC and total neonatal hearts were used as controls. kDa kilodalton, Mw molecular weight.
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ischemic hearts, more specifically in the infarct zone (SI Fig. S3). This observation is in line with the significant 
increase in cardiac  PW1+ cell population post-MI, predominantly in the infarct  area19. These results indicate that 
αV-integrin (CD51) is expressed in almost all cardiac  PW1+ cells, and predominantly found in the cells express-
ing PW1 in the myocardium.
Cardiac  PW1+ and  CD51+ cells express fibrogenic genes. To better characterize the  PW1+CD51+ 
cardiac cell population, we first investigated the RNA-seq data for the expression of known markers of major cell 
 types25, including fibroblasts (col1a1, Pdgfra), pericytes (Pdgfrb), smooth muscle cells (Acta2), Schwann cells 
(plp1), myeloid leukocytes (cd64/Fcgr1, cd209a, S100a9) and CMs (tnni3, tnnt2, tnnc1) as well as Peg3 (encoding 
PW1) and Itgav (encoding CD51). In comparison to CMs and non-CMs, FACS-isolated cardiac  PW1+ cells from 
normal mouse hearts showed higher expression of Itgav and a hybrid molecular signature of fibroblasts, mac-
rophages and to a slightly lower extent of pericytes (Fig. 4A). Hierarchical clustering further revealed the higher 
expression level of collagen genes in cardiac  PW1+ cells than in other cell populations (Fig. 4B), suggesting that 
cardiac  PW1+CD51+ cells exhibit fibroblast-like transcriptional signature.
To further confirm the cellular identity of cardiac  PW1+  CD51+ cells, we analyzed Peg3 and Itgav expressions 
in single-cell RNA-seq profiles of murine cardiac non-myocytes  cells25. As a result, we observed that both markers 
did not specifically tag any cell population but were primarily expressed in fibroblasts, pericytes and Schwann 
cells at high levels (Fig. 4C); low level expression was detected in other cell populations such as smooth muscle 
cells, and endothelial cells. Per-cell gene expression measurements are sparse in droplet single-cell RNA-seq 
data, making it difficult to infer gene co-expression within single cells with high confidence. Nevertheless, joint 
expression of both markers was the highest in fibroblasts (Fig. 4C), supporting our previous report (Fig. 4A,B 
 and19) that cardiac  PW1+CD51+ cells are predominantly identified as fibroblasts or cells involved in fibrotic 
tissue remodeling.
Cardiac  PW1+ cells express different αV‑containing integrins. αV-integrin (CD51) belongs to the 
family of integrins that are transmembrane receptors which act as bridges for cell–ECM connections and cell–
cell interactions. αV-integrin subunits can combine to beta subunits to form different integrin combinations 
depending on specific cell types. To investigate whether there exists an integrin complex specific to  PW1+ cardiac 
stromal cells, we assessed the expression of Peg3, Itgav, and genes encoding beta subunits (including Itgb1, Itgb3, 
Itgb5, and Itgb8) in different murine non-myocytes cardiac cells using single-cell RNA seq data (Fig. 4D). We 
found that the mRNA expression level of Itgb1 was higher among all other beta subunits and in almost all cell 
types including fibroblasts, which showed the highest expression levels of Peg3 and Itgav. Thus, αVβ1 complex is 
predominantly associated with cardiac  PW1+ cells. Western blotting for cardiac cell fractions (SI Fig. S4A) con-
firmed the presence of ITGβ1, ITGβ3, ITGβ5, and ITGβ8 in non-CMs. The expression of ITGβ1 and ITGβ3, but 
not ITGβ5 and ITGβ8, on cardiac  PW1+ cells was further confirmed with western blotting (Fig. 4E; SI Fig. S4B). 
In addition, ITGβ1 and ITGβ3 were overexpressed in the infarct areas of post-MI hearts as compared to controls 
(SI Figs. S5, S6). Overall, these results confirm the high expression of αV-integrin (CD51) and ITGβ1 and ITGβ3 
on cardiac  PW1+ cells, and suggest the presence of complexes consisting of αVβ1 and αVβ3 heterodimers.
αV‑integrin blockade reduces the profibrotic ability of cardiac  PW1+ cells. Recent studies have 
shown that αV-integrin functions as the central mediator of organ fibrosis through TGFβ  activation22,23, in par-
ticular αVβ1 integrin. As our data indicate the presence of the αVβ1 complex on cardiac  PW1+ cells, we inves-
tigated whether αV-integrin (CD51) blockade could directly affect the contribution of cardiac  PW1+ cells to 
fibrosis. αV-integrin recognizes and binds the tripeptide sequence RGD (arginine, glycine, aspartic acid), a key 
motif for cell–cell and cell–ECM interactions. Based on this motif, a cyclic RGD pentapeptide was developed 
(called cilengitide) and shown to inhibit αV-integrin activity, including αVβ1, αVβ3, and αVβ5 activity.
We first FACS-isolated and cultured cardiac  PW1+CD51+ cells, which were then incubated with latent TGFβ 
in presence or absence of the anti-integrin drug cilengitide for 24 h. Using HEK-Blue TGFβ reporter cells that 
allow the detection of bioactive TGFβ by monitoring the activation of the TGFβ/Smad pathway (Fig. 5A), we 
found a significant reduction in the levels of active TGFβ in the supernatants of  PW1+CD51+ cells treated with 
cilengitide as compared to vehicle (Fig. 5B). This observation highlights the direct contribution of  PW1+CD51+ 
cells in the activation of the fibrosis mediator TGFβ.
In addition, cilengitide treatment affected the expression of profibrotic genes in cultured cardiac  PW1+ cells, 
as evident from the significant downregulation in the levels of Acta2, Mmp2, and Tgfrb1 (SI Fig. S7). This result is 
Figure 4.  Cardiac  PW1+CD51+ cells express a fibrogenic program. (A) Hierarchical clustering based on the 
expression of Peg3, Itgav, and known cell type markers in FACS-isolated  PW1+ cells, cardiomyocytes, and non-
myocyte fractions from normal mouse hearts. (B) Hierarchical clustering showing high expression of collagen 
genes in  PW1+ cells. (C) Expression of Peg3 (yellow) and Itgav (blue) in major cardiac cell populations identified 
after unsupervised clustering of single-cell RNA-sequencing data as previously  reported25. Each point depicts 
a single cell. Principal component analysis and t-distributed stochastic neighbor embedding (t-SNE) were 
performed to provide a 2D mapping of clusters. Joint expression of Peg3 and Itgav within single cells is showed 
in purple. (D) The abundance of Peg3 and Itgav mRNAs and those encoding Itgβ1, Itgβ3, Itgβ5, and Itgβ8 
according to cell types identified using single-cell RNA-sequencing from normal mouse hearts. (E) Western 
blots for ITGβ1, ITGβ3, ITGβ5, and ITGβ8 in  PW1+ versus  PW1− cardiac fractions. Proteins from HUVEC cells 
and neonatal mouse heart were used as positive controls. Ponceau Red staining showed equal protein loading.
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suggestive of the reduction in TGFβ signaling and myofibroblast differentiation capacity. Col1a1 expression was, 
however, unaffected by cilengitide treatment, supporting the specific regulatory role on individual ECM genes.
Targeting  PW1+ αV‑integrin reduce cardiac fibrosis after MI. We examined the potential of the 
pharmacological blockade of αV-integrin to prevent cardiac fibrosis in response to ischemic injury. Mice were 
pre-treated for 7 days with cilengitide or vehicle and then subjected to MI via a complete LAD ligation. Mice were 
daily treated with cilengitide or vehicle for 7 additional days before the final evaluation of cardiac function and 
remodeling (Fig. 5C). We found that cilengitide treatment significantly improved the animal survival (Fig. 5D) 
and significantly increased their cardiac functions, as analyzed by left ventricular ejection fraction (Fig. 5E). 
Staining for collagen (Masson trichrome and Sirius red) was performed on eight sequential cardiac sections 
(Fig. 5F). Digital image quantification demonstrated a significant reduction in the infarct size (38.8% ± 7.9% 
versus 56.8% ± 14.9% in cilengitide versus vehicle, P = 0.0008, Fig. 5G) and interstitial fibrosis measured in the 
remote myocardial area (15.9% ± 10.4% versus 36.8% ± 13.1% in cilengitide versus vehicle, P < 0.0001, Fig. 5H) 
following cilengitide treatment, which was not associated with any changes in survival, cardiac function, or 
cardiac fibrosis in sham animals (SI Fig. S8). There were no significant differences in scar thickness between 
groups (Fig. 5G).
As these results suggest a reduction in the mechanisms leading to the development of cardiac fibrosis in 
response to MI, we used the stability (produrance) of the β-gal reporter to perform short-term lineage tracing 
of cells derived from β-gal+ cells (i.e., cardiac  PW1+ cells) using the  PW1nLacZ-reporter mouse model. We exam-
ined β-gal activity and expression of αSMA as a marker of activated fibroblasts in vivo in post-MI (7 days) heart 
sections. As a result, we found that cilengitide treatment significantly reduced the total number of αSMA+ cells 
(Fig. 6A,B) and the proportion of cells co-expressing β-gal and αSMA (Fig. 6C) and significantly increased the 
number of β-gal+ cells lacking αSMA expression (Fig. 6D). In addition, we also found a significantly higher num-
ber of  CD31+αSMA+ vessels in the border zone in cilengitide-treated animals as compared to vehicle (Fig. 6E,F). 
Overall, these results suggest that αV-integrin blockade with cilengitide affects the ability of cardiac  PW1+ cells 
to differentiate into fibroblasts and contribute to fibrotic scarring and contributes to the preservation of vascu-
lature in the border areas.
Discussion
To the best of our knowledge, here we provide the first description of the proteins expressed on the surface of 
cardiac  PW1+ cells and identify a novel target to suppress the fibrogenic behavior of these cells, resulting in 
favorable outcomes in post-MI cardiac remodeling and animal survival.
The transgenic PW1 reporter mouse model has facilitated the identification of  PW1+ cells and demonstrated 
the importance of PW1 as a pan-tissue stem cell  marker19,20,26–28. Herein, we used this model to specifically isolate 
cardiac  PW1+ cells and adopt a multi-omic unbiased approach to further decipher the cell surface membranome 
of these cells. The transcriptomic predictions allowed filtering of a large number of membrane proteins identi-
fied through MS technique and, hence, increased the likelihood of identification of a more specific cell surface 
marker among the limited number of shortlisted candidates. A similar approach was recently proposed to define 
the secretome of bone marrow stem  cells29. Here, we have further expanded this approach by adding a proteome 
membrane expression profiling in order to better specify candidates among the large set of candidates generated 
by the transcriptomic predictions. The overlap between the transcriptomic and proteomic datasets led to the 
selection of more specific and relevant candidates.
We found αV-integrin (CD51) is expressed on the majority of cardiac  PW1+ cells which was not previously 
reported or anticipated. Data on the expression of CD51 in cardiac cells are limited and CD51 was previously 
reported to be expressed on > 90% of cardiac fibroblasts cultivated in vitro for 5 days after  isolation30. RNA-seq 
of the freshly isolated cells revealed the positive expression of CD51 on freshly isolated cardiac  PW1+ cells, 
which exhibited a fibroblast-like gene signature. Single-cell RNA-seq analysis showed that both markers did not 
specifically tag a single cell population but were mostly expressed in fibroblasts, further supporting the notion 
that cardiac  PW1+CD51+ cells comprise a subpopulation within the heterogeneous population of cells com-
monly referred as cardiac fibroblasts. Reciprocally, αV-integrin (CD51) expression was predominantly detected 
on cells expressing  PW1+ in the myocardium, thereby highlighting the discriminative value of this new marker 
Figure 5.  Cilengitide reduces cardiac fibrosis and improves cardiac function after MI. (A) Design of the in vitro 
experiments to test the ability of isolated  PW1+CD51+ cardiac cells to activate latent TGFβ. (B) TGFβ levels in 
isolated  PW1+CD51+ cardiac cells supplemented with latent TGFβ and treated with or without the anti-integrin 
drug cilengitide (10 µM final concentration). Results are normalized to absolute values measured in vehicle-
treated group. N = 9 from three independent isolates. ****P < 0.0001 using Mann–Whitney test between groups. 
(C) Experimental design: Mice were pre-treated for 7 days with cilengitide or vehicle (N = 16 per groups) before 
MI induction (Day 0) and then treated for 7 additional days. (D) Survival curves of cilengitide- and vehicle-
treated mice 7 days after MI. *P < 0.05, log-rank test. (E) Left ventricular ejection fractions of cilengitide- and 
vehicle-treated mice immediately before surgery and 7 days later. **P < 0.01, ****P < 0.0001. (F) Analysis of 
infarct size and cardiac fibrosis between cilengitide- and vehicle-treated mice 7 days after MI was performed at 8 
levels below the LAD ligation site. (G) Masson trichome staining in vehicle- and cilengitide-treated animals and 
quantification of infarct size and scar thickness between both groups, ***P < 0.001 (N = 4 per group). (H) Sirius 
red staining in vehicle- and cilengitide-treated animals and quantification of interstitial fibrosis in remote areas 
between both groups, ****P < 0.0001, (N = 4 per group). Data are mean ± SD. Drawings are from servier medical 
art (https ://smart .servi er.com) which is licenced under a creative commons attribution 3.0 unported license.
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Figure 6.  Cilengitide reduces the profibrotic activation of cardiac  PW1+ cells. (A) Representative cardiac 
sections (in the infarct zone) from vehicle- and cilengitide-treated mouse hearts immunostained with αSMA 
(green), β-gal (red), and DAPI (blue). White arrows indicate β-gal single-positive cells. (B) Quantification of 
αSMA+ cells within the total number of cells per field in vehicle- and cilengitide-treated post-MI hearts. (C) 
Quantification of β-gal+αSMA+ cells within the total number of cells per field in vehicle- and cilengitide-treated 
post-MI hearts. (D) Quantification of β-gal+ cells within the αSMA-negative cells in vehicle- and cilengitide-
treated post-MI heart sections. (E) Representative cardiac sections (in the border zone) from vehicle- and 
cilengitide-treated mouse hearts immunostained with αSMA (green), CD31 (red), and DAPI (blue). (F) 
Quantification of  CD31+αSMA+ vessels in the border zone in vehicle- and cilengitide-treated post-MI hearts. 
N = 18 fields at least from two animals per groups, *P < 0.05, **P < 0.01 and ***P < 0.001. Data are mean ± SD.
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that could henceforth be useful for  PW1+ cell sorting. Whether αV-integrin (CD51) specifically tags  PW1+ cells 
in non-cardiac organs, however, remains to be determined.
The identification of this new cell surface marker provides important information on the pathophysiological 
role of cardiac  PW1+ cells. CD51 is an αV-integrin subunit, a subset of the integrin family cell adhesion receptors 
that was thought to serve as a central mediator of organ fibrosis through TGFβ  activation22,23. Our results indicate 
that αV-integrin expressed by cardiac  PW1+ cells activate latent TGFβ and that the pharmacological blockade 
of αV-integrin could reduce TGFβ activation in vitro and cardiac fibrosis post-MI in vivo. This new observa-
tion is consistent with our previous findings that cardiac  PW1+ cells display a fibrogenic behavior in response 
to ischemic injury, notably by directly giving rise to  fibroblasts19. However, the pharmacological blockade of 
αV-integrin could suppress the expression of fibrotic genes in isolated cardiac  PW1+ cells and reduce their ability 
to differentiate into fibroblasts in vivo post-MI, suggestive of the role of αV-integrin as a regulator of multiple pro-
fibrotic mechanisms. Overall, our results are compatible with the hypothesis that cardiac  PW1+ cells represent a 
source of fibrosis by directly differentiating into fibroblasts as well as by orchestrating a microenvironment that 
further favors the activation of resident fibroblasts or remodeling of the ECM.
Pharmacological blockade of αV-integrin with cilengitide in this model significantly reduced post-MI fibrotic 
remodeling, consistent with the significant reduction in infarct size and interstitial fibrosis but without any 
increase in the rate of cardiac rupture. The survival and cardiac function of cilengitide-treated animals conse-
quently improved. Our study thus suggests the potential development of a new anti-fibrotic therapy by targeting 
αV-integrin expressed on fibrogenic cardiac  PW1+ cells. So far, HF therapies are directed to alleviate cardiac 
workload and indirectly reduce cardiac remodeling; however, there is no effective anti-fibrotic therapeutic strat-
egy that could complement the current therapies for  HF9,11,12. Anti-fibrotic strategies in MI are often associated 
with the risk of cardiac rupture by limiting the development of replacement fibrosis, which restores the region 
devoid of viable CMs and prevents cardiac  rupture31. For instance, it was recently shown that strategies that limit 
inflammatory cell recruitment to the site of infarction delayed the removal of dead CMs and their replacement by 
a scar tissue, consequently increasing the susceptibility to cardiac  rupture32. We failed to observe such an adverse 
outcome, instead noticed significant improvements in mouse survival after cilengitide treatment. The significant 
reduction in interstitial fibrosis in cilengitide-treated animals suggests that the blockade of αV-integrin does 
not directly affect the replacement fibrotic remodeling but rather limits the development of reactive interstitial 
fibrosis in the viable  myocardium12. The role of integrins in non-cardiac organ fibrosis (i.e., lung and liver) is 
being increasingly recognized, and genetic deletion or pharmacological inhibition of integrin was shown to be 
associated with reduced fibrotic  remodeling23,33,34. Interestingly, these recent studies indicate the critical role 
of αVβ1 in organ  fibrosis23,33. Our data show co-expression of αV-integrin and ITGβ1 in cardiac  PW1+ cells 
although we do not provide evidence that these molecules are dimerized. Indeed. the roles of αVβ1 heterodimers 
as well as mesenchymal-like cells αV integrins in the development of muscular and cardiac fibrosis have only 
been recently  reported23,35. We therefore provide evidence for the role of cardiac  PW1+ αV-integrin cells in the 
development of cardiac fibrosis. Additional experiments are needed to decipher the expression and functional 
role of αV-heterodimers within the different populations of cardiac cells.
Our study has some limitations that should be acknowledged. First, integrins are expressed on a variety 
of cells. αV-integrin is expressed on endothelial cells and cilengitide is thought to exert some anti-angiogenic 
 effects36. It is unlikely that the observations reported herein could be attributed to the anti-angiogenic effects 
of cilengitide, as these effects would rather contribute to the adverse deterioration of cardiac function and 
remodeling post-MI. We rather found an increase in small vessel in the border zone of cilengitide-treated ani-
mals, suggesting a beneficial effect on vasculature. ITGβ3 is similarly expressed by endothelial cells; however, 
we observed a significant increase in ITGβ3 expression level in the infarct area, a region typically depleted of 
vessels but enriched with  PW1+ cells. Overall, this result suggests that the observed benefit with cardiac fibrotic 
remodeling is primarily associated with the reduction in the fibrogenic behavior of cardiac  PW1+ cells and to a 
potential benefit on the vascular compartment. The contribution of circulating cells (such as inflammatory cells 
in response to CM necrosis) may however not be ruled out. Similarly, we did not explore the effect of cilengitide 
on immune and inflammatory responses after MI, but there is currently no evidence of an action of cilengitide 
on immune cells. This issue would deserve further investigations. In addition, we did not explore whether PW1, 
as a transcription factor, directly controls the expression of fibrotic genes. Constitutive Peg3/PW1 knock-out 
mice were recently generated and showed reduction in post-natal growth, supporting the direct role of PW1 in 
the regulation of tissue  growth37. Further experiments with inducible-knockout mouse models would be war-
ranted to address this question. Importantly, we cannot rule out a contribution of other cell types as αV-integrin 
expression was also observed on a small proportion of cells which do not express PW1 (Fig. 3D,E).
Our results provide a route to translate towards a clinical setting as anti-CD51 antibodies (namely abituzumab 
and intetumumab) and small molecules have recently been developed and have entered into phase 1/2 clinical 
trials. These molecules were developed to primarily block cell proliferation, adhesion, and migration in relation 
to the function of αV-integrin and have thus been tested in patients with cancer, although with modest  efficacy38. 
Our study indicates that these molecules could be repurposed for the treatment of fibrotic disorders, including 
post-MI cardiac fibrosis.
Conclusions
Overall, these data identify cardiac  PW1+ cells as a source of cardiac fibrosis in response to ischemic injury via 
αV-integrin and suggest that the pharmacological targeting of αV-integrin may offer clinical benefits in the 
treatment of cardiac ischemia.
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Methods
Additional description of experiments is provided in the supplemental material appendix.
All procedures and animal care protocols were approved by our institutional research committee (CEEA34 
and French ministry of research) and conformed to the animal care guideline in Directive 2010/63/EU European 
Parliament. All animals received humane care in compliance with the “Principles of Laboratory Animal Care” 
formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory 
Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of 
Health (NIH Publication No. 86-23, revised 1996).
Study design. Left anterior descending artery (LAD) surgery was performed on 8-week-old male C57BL/6J 
and PW1-reporter  (PW1nLacZ) mice, which were anesthetized in an induction chamber with 2% isoflurane mixed 
with 1.0 L/min 100%  O2 and placed in a supine position on a heating pad to maintain body temperature. The 
mice were intubated with endotracheal tube and then connected to a rodent ventilator (180 breaths/min and a 
tidal volume of 200 µL). During surgical procedure, anesthesia was maintained at 1.5–2% isoflurane with  O2. 
The chest was accessed from the left side through the intercostal space, and the pericardium incised. The LAD 
was exposed and encircled with an 8-0 prolene suture at the proximal position. The suture was briefly snared to 
confirm the ligation by blanching the arterial region. For in vivo pharmacological studies, cilengitide (10 mg/
kg; AdooQ Bioscience) was daily intraperitoneally administered to mice 7 days before and then 7 days after MI 
in line with previous  reports39. Mice from the control group were treated with vehicle. At day 7 after surgery, 
animals were euthanatized and hearts were carefully excised, fixed in paraformaldehyde 4% and then incubated 
with 30% sucrose solution overnight. Hearts were immersed in optimum cutting temperature (OCT) embed-
ding medium and immediately frozen in liquid nitrogen vapors.
Measurement of cardiac parameters. Echocardiographic measurements were performed at day 0 and 
7 after surgery to assess cardiac function using two-dimensionally guided Time Motion mode recording (Vivid7 
PRO apparatus, GE Medical System Co). Each set of measurements was obtained from the same cardiac cycle.
Cell isolation and fluorescence‑activated cell sorting (FACS). Cells were sorted from the whole 
heart (upon atria removal) of 8-week-old  PW1nLacZ mice as previously  described19. Briefly, after mouse euthana-
sia, hearts were perfused with phosphate-buffered saline (PBS) to flush out any residual blood cells. Ventricles 
were finely minced (0.5–1 mm3) and then enzymatically digested for 30 min at 37 °C with a 480 U/mL colla-
genase II (Worthington) solution in PBS. Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) sup-
plemented with 10% fetal bovine serum (FBS, Sigma) and 1% penicillin/streptomycin (P/S) (Life Technologies) 
was added to terminate digestion, and the obtained cell suspension was filtered through a 100 µm cell strainer 
before centrifugation at 400×g and 4 °C for 10 min. Red blood cell lysing (RBCL) buffer was added to the cell 
pellet to lyse red blood cells. The reaction was terminated with Hanks’ Balanced Salt solution (Gibco) containing 
1% FBS (HBSS-1% FBS), followed by centrifugation under same conditions as above. Cell suspension was then 
stained on ice for 45 min in the dark with several antibodies, listed in SI Table S1, diluted in HBSS-1% FBS. Cells 
were rinsed with HBSS-1% FBS and centrifuged before staining for PW1.
To detect β-gal reporter activity  (PW1+ cells), cells were incubated in the dark with HBSS-1% FBS contain-
ing 60 µM of the β-gal substrate 5-dodecanoylaminofluorescein di-β-d-galactopyranoside (C12FDG, Thermo 
Fisher Scientific) at 37 °C for 1 h under constant agitation. HBSS-1% FBS was added to stop the reaction. After 
centrifugation, the samples were incubated with propidium iodide (Sigma) and then filtered using a 50 µm Fil-
con (BD bioscience) before analysis. The different populations were gated, analyzed, and sorted on a FACS Aria 
II cytometer (BD Biosciences). Viability threshold was determined by comparing conditions with and without 
PI. All immunostained populations were obtained by comparing signals from unstained cells and fluorescence 
minus one conditions. β-Gal activity threshold was obtained by comparing β-gal-negative and -positive cells.
RNA sequencing (RNA‑seq). In total, 300 ng of total RNA extracted from freshly isolated cells with Sure-
Select Strand-Specific RNA kit (Agilent) was used to prepare a library, according to the manufacturer’s instruc-
tions. The resulting library was quality checked and quantified by peak integration on Bioanalyzer High sensitiv-
ity DNA labchip (Agilent). A pool of equal quantity of 12 purified libraries was prepared, and each library was 
tagged with a different index. mRNAs pool libraries were finally sequenced on Illumina Hiseq 1500 instrument 
using a rapid flowcell. The pool was loaded on two lanes of the flowcell. A paired-end sequencing of 2 × 100 bp 
was performed.
After discarding reads that did not pass the Illumina filters and trimming low-quality sequenced bases (q < 28) 
using the Cutadapt  program40, we restricted our downstream analyses to reads with lengths greater than 90 bp. 
Selected reads were mapped to a murine reference transcriptome that was generated by the RSEM  package41 
from the full mouse reference genome and the gtf transcript annotations file from  ENSEMBL42. Alignment 
and estimation of transcripts abundance in each of the 12 processed samples were performed using the RSEM 
program. Transcripts with abundance counts higher than 10 in more than two samples (N = 36,948) were con-
sidered as expressed and retained for further analysis. Abundances of transcripts assigned to the same gene were 
combined together, leading to the profiling of 16,403 genes. Analyses were conducted under the R environment 
(version 3.2.2).
Galaxy 15.10 instance was locally installed on a server machine. WolfPsort, TMHMM, and SignalP were 
obtained from CBS prediction servers (https ://servi ces.healt htech .dtu.dk/, accessed April 15th, 2020). NLStrada-
mus and PredictNLS were used in parallel to determine nuclear localization signals. Each dataset from RNA-seq, 
corresponding to a different population, was then processed through a pipeline designed to select sequences 
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containing a signal peptide, at least one transmembrane segment, no nuclear localization signal, and a theoretical 
presence at the plasma membrane. All samples were compared, and a list of candidates that were only expressed 
in  PW1+ cells under normal and post-MI conditions was obtained.
Single‑cell RNA‑seq. Single cell RNA-seq data were obtained from a previously published study of car-
diac non-myocytes isolated from left ventricles of 10-week-old mice at  homeostasis25. Cell-type labels for each 
cell profiled in this previous study are available at the following URL: https ://githu b.com/daske lly/CellR eport 
s_2018_heart _scRNA seq. Data were analyzed and plots were constructed with the Seurat package version 2.3.443 
using the R environment for statistical computing version 3.5.044.
PW1+CD51+ cell culture and TGFβ supernatant assay. FACS-sorted cells were seeded at a density 
of 25,000 cells per  cm2 in culture plates coated with attachment factor (Thermo Fisher Scientific) in DMEM 
supplemented with 10% FBS and 1% P/S. The culture medium was changed the day after and treatments were 
performed on day 5.
For the analysis of the activation of latent transforming growth factor beta (TGFβ),  PW1+CD51+ cells were 
incubated in a medium supplemented with latent TGFβ (1.1 ng/mL final concentration) in the presence of 
cilengitide (10 μM final concentration) or vehicle for 24 h at 37 °C. HEK-Blue TGFβ cells (InvivoGen) were 
seeded in 24-well plates at a density of 20,000 cells/well in the same medium as  PW1+CD51+ cells. Following 
attachment, these cells were incubated with the supernatant from  PW1+CD51+ cells treated with latent TGFβ 
and cilengitide or vehicle. Internal positive controls included HEK-Blue cells treated with active TGFβ (3 ng/
mL final concentration), while the negative control was HEK-Blue cells treated with latent TGFβ (1.1 ng/mL) 
in medium. Following overnight incubation, 100 μL of medium from cells under each treatment condition was 
collected and incubated with 160 μL of Quanti-Blue medium in 96-well plates at 37 °C for 2 h. The absorbance 
was measured at 625 nm wavelength using a plate reader (FlexStation 3, Molecular Devices).
For  PW1+ cell transcriptional signature analysis after cilengitide treatement,  PW1+ cells were stimulated with 
300 and 1,000 nM of cilengitide. At day 6, medium was removed and cells were washed twice with PBS before 
RNA extraction following manufacturer’s protocol (PureLink™ RNA mini kit, Life Technologies). RNA was con-
verted to cDNA using the SuperScript IV First-Strand Synthesis System (Thermo Fisher Scientific) to perform 
quantitative polymerase chain reaction (q-PCR) (Sybr Select Master Mix, Life Technologies) for the analysis of 
expression of selected fibrosis markers. The list of primers used is reported in SI Table S2.
Statistical analysis. The data are expressed as mean ± standard deviation (SD). Quantitative data were ana-
lyzed using one-way analysis of variance (ANOVA) and pair-wise comparisons with Tukey’s test for multiple 
comparisons. The Mann–Whitney U test was used for comparing continuous variables between two groups. A 
log-rank (Mantel–Cox) test was employed to compare survival between groups. A value of P < 0.05 was consid-
ered significant. All analyses were performed by using GraphPad Prism 7.
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